Using Point of Care Testing to estimate influenza vaccine effectiveness in the English primary care sentinel surveillance network
- PMID: 33705452
- PMCID: PMC7951853
- DOI: 10.1371/journal.pone.0248123
Using Point of Care Testing to estimate influenza vaccine effectiveness in the English primary care sentinel surveillance network
Abstract
Introduction: Rapid Point of Care Testing (POCT) for influenza could be used to provide information on influenza vaccine effectiveness (IVE) as well as influencing clinical decision-making in primary care.
Methods: We undertook a test negative case control study to estimate the overall and age-specific (6 months-17 years, 18-64 years, ≥65 years old) IVE against medically attended POCT-confirmed influenza. The study took place over the winter of 2019-2020 and was nested within twelve general practices that are part of the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), the English sentinel surveillance network.
Results: 648 POCT were conducted. 193 (29.7%) of those who were swabbed had received the seasonal influenza vaccine. The crude unadjusted overall IVE was 46.1% (95% CI: 13.9-66.3). After adjusting for confounders the overall IVE was 26.0% (95% CI: 0-65.5). In total 211 patients were prescribed an antimicrobial after swab testing. Given a positive influenza POCT result, the odds ratio (OR) of receiving an antiviral was 21.1 (95%CI: 2.4-182.2, p = <0.01) and the OR of being prescribed an antibiotic was 0.6 (95%CI: 0.4-0.9, p = <0.01).
Discussion: Using influenza POCT in a primary care sentinel surveillance network to estimate IVE is feasible and provides comparable results to published IVE estimates. A further advantage is that near patient testing of influenza is associated with improvements in appropriate antiviral and antibiotic use. Larger, randomised studies are needed in primary care to see if these trends are still present and to explore their impact on outcomes.
Conflict of interest statement
SdeL receives research funding via the University of Surrey from Eli Lilly Co., GlaxoSmithKline, Takeda, AstraZeneca and Novo Nordisk Ltd. TC has also taken part in advisory board meetings for Roche and Janssen, and is a member of independent datamonitoring committees for trials sponsored by Roche. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors have declared no competing interests
Similar articles
-
Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland.Influenza Other Respir Viruses. 2024 Dec;18(12):e70023. doi: 10.1111/irv.70023. Influenza Other Respir Viruses. 2024. PMID: 39623514 Free PMC article.
-
Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.Euro Surveill. 2013 Jan 31;18(5):20390. doi: 10.2807/ese.18.05.20390-en. Euro Surveill. 2013. PMID: 23399425
-
Influenza Vaccine Effectiveness in the Netherlands from 2003/2004 through 2013/2014: The Importance of Circulating Influenza Virus Types and Subtypes.PLoS One. 2017 Jan 9;12(1):e0169528. doi: 10.1371/journal.pone.0169528. eCollection 2017. PLoS One. 2017. PMID: 28068386 Free PMC article.
-
Assessment of the benefits of seasonal influenza vaccination: Elements of a framework to interpret estimates of vaccine effectiveness and support robust decision-making and communication.Influenza Other Respir Viruses. 2021 Jan;15(1):164-174. doi: 10.1111/irv.12786. Epub 2020 Sep 3. Influenza Other Respir Viruses. 2021. PMID: 32885610 Free PMC article. Review.
-
Point of Care Testing for Infectious Disease in Europe: A Scoping Review and Survey Study.Front Public Health. 2021 Oct 20;9:722943. doi: 10.3389/fpubh.2021.722943. eCollection 2021. Front Public Health. 2021. PMID: 34746078 Free PMC article.
Cited by
-
Postpandemic Sentinel Surveillance of Respiratory Diseases in the Context of the World Health Organization Mosaic Framework: Protocol for a Development and Evaluation Study Involving the English Primary Care Network 2023-2024.JMIR Public Health Surveill. 2024 Apr 3;10:e52047. doi: 10.2196/52047. JMIR Public Health Surveill. 2024. PMID: 38569175 Free PMC article.
-
The Impact of Point-of-Care Testing for Influenza on Antimicrobial Stewardship (PIAMS) in UK Primary Care: Protocol for a Mixed Methods Study.JMIR Res Protoc. 2023 Jun 16;12:e46938. doi: 10.2196/46938. JMIR Res Protoc. 2023. PMID: 37327029 Free PMC article.
-
Integrated respiratory surveillance after the COVID-19 pandemic.Lancet. 2022 Dec 3;400(10367):1924-1925. doi: 10.1016/S0140-6736(22)02325-X. Lancet. 2022. PMID: 36463902 Free PMC article. No abstract available.
-
Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform.Front Public Health. 2023 Jul 20;11:1195409. doi: 10.3389/fpubh.2023.1195409. eCollection 2023. Front Public Health. 2023. PMID: 37546295 Free PMC article.
-
The Impact of Point-of-Care Testing for Influenza on Antimicrobial Stewardship in UK Primary Care: Nested Cohort Study.JMIR Public Health Surveill. 2025 Jul 15;11:e72322. doi: 10.2196/72322. JMIR Public Health Surveill. 2025. PMID: 40663790 Free PMC article.
References
-
- Fact sheet Influenza (Seasonal). 2016; Available from: http://www.who.int/mediacentre/factsheets/fs211/en/.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical